from day
one forward
Read our 2018 Annual Report featuring our vision, mission and values, employee stories and videos, business highlights and selected financial information.
Learn More
dedicating decades
to cancer research
Professor Ignace Vergote conducts 20 ovarian cancer trials per year and has authored more than 800 papers in gynecologic cancers. He was an investigator in Novocure’s phase 2 pilot trial in recurrent ovarian cancer, INNOVATE.
Learn More
a skilled
communicator
Tomoe Kamata, Special Project Manager at Novocure Japan, uses her background in science and knack for interacting with people to market Novocure’s cancer therapy in Japan.
Learn More
the story
of Novocure
In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 495 employees and operations in the U.S., Europe and Asia.
Learn More
we can leverage physics to fight cancer
Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
OUR THERAPY
explore our clinical pipeline
Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.
OUR PIPELINE
we are dedicated to improving the lives of cancer patients
Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.
PATIENT-FORWARD